Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Inflammation

Chronic obstructive pulmonary disease (COPD)

IL-33 (NF-HEV)

Mouse and human ex vivo studies suggest inhibiting IL-33 could help treat COPD. In a mouse model of COPD, IL-33 levels were higher in lung progenitor cells than in cells from healthy mice. In the same model, knockout of an essential IL-33 receptor subunit or treatment with a neutralizing antibody targeting that subunit both decreased disease severity compared with no knockout or with control IgG treatment. In lung tissue samples from patients with COPD, IL-33 levels were higher in lung progenitor cells than in samples from individuals without COPD. Next steps include developing inhibitors against IL-33 and its receptor.

SciBX 6(36); doi:10.1038/scibx.2013.999
Published online Sept. 19, 2013

Unpatented; licensing status not applicable

Byers, D.E. et al. J. Clin. Invest.; published online Aug. 15, 2013;
doi:10.1172/JCI65570
Contact: Michael J. Holtzman, Washington University in St. Louis School of Medicine, St. Louis, Mo.
e-mail:

holtzmanm@wustl.edu